AZD1152-HQPA (barasertib) is a highly selective Aurora B kinase inhibitor [13] with efficacy on a wide variety of tumor entities, including acute myeloid leukemia, advanced solid tumors, and diffuse large B-cell lymphoma, which has already been investigated and validated in phase I and II studies [14,15,16]. This evidence concerns the gene AURKB and neoplasm.